Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Biomolecules
|
July 12, 2017
MYC-Driven Pathways in Breast Cancer Subtypes
Yassi Fallah, Janetta Brundage, Paul Allegakoen, et al.
Biorxiv : the Preprint Server for Biology
|
November 19, 2025
CDK4 or CDK6 upregulation induces DNA replication stress and genomic instability to cause EGFR targeted therapy resistance in lung cancer
Beatrice Gini, Philippe Gui, Wei Wu, et al.
Biorxiv : the Preprint Server for Biology
|
December 18, 2023
RPL22 is a tumor suppressor in MSI-high cancers and a key splicing regulator of MDM4
Hannah N W Weinstein, Kevin Hu, Lisa Fish, et al.
Nature Communications
|
January 11, 2022
Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states
Hanbing Song, Hannah N W Weinstein, Paul Allegakoen, et al.
Cancers
|
October 27, 2019
The Epithelial to Mesenchymal Transition Promotes Glutamine Independence by Suppressing <i>GLS2</i> Expression
Esmeralda Ramirez-Peña, James Arnold, Vinita Shivakumar, et al.
Cell Reports
|
August 15, 2024
RPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4
Hannah N W Weinstein, Kevin Hu, Lisa Fish, et al.
Nature Communications
|
June 17, 2025
Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression
Heiko Yang, Hanbing Song, Elizabeth Yip, et al.
Iscience
|
January 8, 2026
EMT-induced stem cell and mesenchymal programs can be decoupled via cell division and ESRP1-dependent mechanisms
Petra den Hollander, Maria Castaneda, Suhas V Vasaikar, et al.
Research Square
|
November 24, 2025
Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies
Tadashi Manabe, Hannah C Bergo, Qingtian Li, et al.
Nature Communications
|
February 7, 2026
Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies
Tadashi Manabe, Hannah C Bergo, Qingtian Li, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Biomolecules
|
July 12, 2017
MYC-Driven Pathways in Breast Cancer Subtypes
Yassi Fallah, Janetta Brundage, Paul Allegakoen, et al.
Biorxiv : the Preprint Server for Biology
|
November 19, 2025
CDK4 or CDK6 upregulation induces DNA replication stress and genomic instability to cause EGFR targeted therapy resistance in lung cancer
Beatrice Gini, Philippe Gui, Wei Wu, et al.
Biorxiv : the Preprint Server for Biology
|
December 18, 2023
RPL22 is a tumor suppressor in MSI-high cancers and a key splicing regulator of MDM4
Hannah N W Weinstein, Kevin Hu, Lisa Fish, et al.
Nature Communications
|
January 11, 2022
Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states
Hanbing Song, Hannah N W Weinstein, Paul Allegakoen, et al.
Cancers
|
October 27, 2019
The Epithelial to Mesenchymal Transition Promotes Glutamine Independence by Suppressing <i>GLS2</i> Expression
Esmeralda Ramirez-Peña, James Arnold, Vinita Shivakumar, et al.
Cell Reports
|
August 15, 2024
RPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4
Hannah N W Weinstein, Kevin Hu, Lisa Fish, et al.
Nature Communications
|
June 17, 2025
Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression
Heiko Yang, Hanbing Song, Elizabeth Yip, et al.
Iscience
|
January 8, 2026
EMT-induced stem cell and mesenchymal programs can be decoupled via cell division and ESRP1-dependent mechanisms
Petra den Hollander, Maria Castaneda, Suhas V Vasaikar, et al.
Research Square
|
November 24, 2025
Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies
Tadashi Manabe, Hannah C Bergo, Qingtian Li, et al.
Nature Communications
|
February 7, 2026
Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies
Tadashi Manabe, Hannah C Bergo, Qingtian Li, et al.
Page
of 2